论文部分内容阅读
目的:对比研究联合应用西洛他唑对初诊腔隙性脑梗死患者脂联素(APN)、内皮素-1(ET-1)及血栓调节蛋白(TM)的影响,并探讨其临床意义。方法:连续选取98例初诊腔隙性脑梗死患者为研究对象,按随机数字表法将其分为观察组48例,对照组50例。2组患者除基础治疗外,对照组予以拜阿司匹林片0.1g,1次/d口服。观察组在对照组的基础上联合应用西洛他唑片50mg,2次/d,口服,疗程为12周。检测2组患者血APN、ET-1及TM的变化,并予以比较、分析。结果:①2组患者治疗前APN、ET-1及TM水平相当,差异无统计学意义(P>0.05)。②治疗后2组患者APN水平较同组治疗前明显升高,ET-1及TM水平则降低;其中观察组上述指标改变更为明显,差异具有统计学意义(P<0.01)。结论:联合应用西洛他唑可以使初诊腔隙性脑梗死患者,在抗动脉粥样硬化和保护内皮功能方面获益。
Objective: To compare the effects of cilostazol on the levels of plasma adiponectin (APN), endothelin-1 (ET-1) and thrombomodulin (TM) in patients with newly diagnosed lacunar infarction and to explore its clinical significance. Methods: A total of 98 patients with newly diagnosed lacunar infarction were enrolled in this study. According to the random number table, they were divided into observation group (48 cases) and control group (50 cases). In addition to the two groups of patients with basic treatment, the control group to be aspirin tablets 0.1g, 1 / d orally. Observation group in the control group based on the combination of cilostazol tablets 50mg, 2 times / d, oral, treatment for 12 weeks. The changes of blood APN, ET-1 and TM in two groups were detected and compared. Results: ① The levels of APN, ET-1 and TM before treatment in group 2 were similar, with no significant difference (P> 0.05). ② After treatment, the levels of APN in the two groups were significantly higher than those before treatment, and the levels of ET-1 and TM were decreased. The changes of the above indexes in the observation group were more obvious, the difference was statistically significant (P <0.01). Conclusion: The combination of cilostazol can benefit newly diagnosed patients with lacunar infarction in anti-atherosclerosis and endothelial protection.